Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study Article uri icon

Overview

MeSH Major

  • Hematopoietic Stem Cell Transplantation
  • Lymphoma, T-Cell, Peripheral

publication date

  • January 2019

Research

keywords

  • In Process

Identity

Digital Object Identifier (DOI)

  • 10.1002/ajh.25387

Additional Document Info